Gelsolin and Adipokines Are Associated With Protein-Energy Wasting in Hemodialysis Patients

Artificial Organs

Volumn 39, Issue 2, 2015, Pages 150-155

  Chiu, Terry Ting Yu ^a   Liao, Shang Chih ^a   Lee, Wen Chin ^a   Lee, Po Shun ^b   Ng, Hwee Yeong ^a   Chien, Yu Su ^a   Lee, Chien Te ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adiponectin; Gelsolin; Hemodialysis; Leptin; Protein energy wasting

Indexed keywords

BODY FLUIDS; HEMODIALYZERS; HORMONES; METABOLISM; PROTEINS; REGRESSION ANALYSIS; UREA;

ADIPOKINES; ADIPONECTIN; ENERGY; GELSOLIN; HAEMODIALYSIS; HEMODIALYSIS PATIENT; LEPTINS; PROTEIN-ENERGY WASTING; RENIN-ANGIOTENSIN SYSTEM; TNF Α;

DIALYSIS;

ADIPONECTIN; ANTILIPEMIC AGENT; CREATININE; GELSOLIN; INTERLEUKIN 6; LEPTIN; NITROGEN; TUMOR NECROSIS FACTOR ALPHA; UREA; ADIPOCYTOKINE; BIOLOGICAL MARKER;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; BODY MASS; CHRONIC GLOMERULONEPHRITIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; END STAGE RENAL DISEASE; FEMALE; GRIP STRENGTH; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN ENERGY WASTING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UREA NITROGEN BLOOD LEVEL; AGED; BLOOD; COMPLICATION; MIDDLE AGED; PROTEIN-ENERGY MALNUTRITION; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

ADIPOKINES; AGED; BIOLOGICAL MARKERS; FEMALE; GELSOLIN; HUMANS; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; PROTEIN-ENERGY MALNUTRITION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922722027     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12342     Document Type: Article

References (26)

1. de Mutsert R, Grootendorst DC, Axelsson J, et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008;23:2957-2964.
2. Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol 2009;29:3-14.
3. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008;73:391-398.
4. Iglesias P, Diez JJ. Adipose tissue in renal disease: clinical significance and prognostic implications. Nephrol Dial Transplant 2010;25:2066-2077.
5. Lee CT, Lee CH, Su Y, Chuang YC, Tsai TL, Chen JB. The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs 2004;27:835-841.
6. Lee CT, Ng HY, Hsu CY, et al. Proinflammatory cytokines, hepatocyte growth factor and adipokines in peritoneal dialysis patients. Artif Organs 2010;34:E222-229.
7. Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol 2007;292:C1323-1330.
8. Bucki R, Byfield FJ, Kulakowska A, et al. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J Immunol 2008;181:4936-4944.
9. Lee PS, Sampath K, Karumanchi SA, et al. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol 2009;20:1140-1148.
10. Williams AJ, McArley A. Body composition, treatment time, and outcome in hemodialysis patients. J Ren Nutr 1999;9:157-162.
11. Lin YC, Yen LL, Chen SY, et al. Prevalence of overweight and obesity and its associated factors: findings from National Nutrition and Health Survey in Taiwan, 1993-1996. Prev Med 2003;37:233-241.
12. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749.
13. Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 2009;24:1876-1883.
14. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation. Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006;147:4160-4168.
15. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
16. Dukkipati R, Noori N, Feroze U, Kopple JD. Dietary protein intake in patients with advanced chronic kidney disease and on dialysis. Semin Dial 2010;23:365-372.
17. Kwiatkowski DJ, Mehl R, Izumo S, Nadal-Ginard B, Yin HL. Muscle is the major source of plasma gelsolin. J Biol Chem 1988;263:8239-8243.
18. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996;335:1897-1905.
19. Takeuchi T, Kotani T, Nakanishi T, Tabushi-Matsumura Y, Takubo T, Makino S. The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol Med 2008;14:582-589.
20. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007;35:849-855.
21. Chan WM, Lau LS, Kwok KM, et al. A randomized, double-blind, placebo-controlled, ascending-dose trial of the pharmacokinetics and safety of intravenous infusion of recombinant human plasma gelsolin in acutely ill patients with decreased plasma gelsolin levels [ATS abstract]. Am J Respir Crit Care Med 2011;183:A5601.
22. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor 1 in rats through a pressor-independent mechanism. J Clin Invest 1996;97:2509-2516.
23. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-1083.
24. Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD. Adiponectinin peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004;43:1047-1055.
25. Nakagawa N, Yao N, Hirayama T, et al. Potential impact of renin-angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients. Hypertens Res 2011;34:592-598.
26. Yamada S. Pleiotropic effects of ARB in metabolic syndrome. Curr Vasc Pharmacol 2011;9:158-161.